Kawasaki, Japan

Michito Sumikawa


Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 106(Granted Patents)


Location History:

  • Yokkaichi, JP (2006 - 2010)
  • Kawasaki, JP (1988 - 2011)

Company Filing History:


Years Active: 1988-2011

Loading Chart...
11 patents (USPTO):Explore Patents

Title: Michito Sumikawa: Innovator in Pharmaceutical Crystallization

Introduction

Michito Sumikawa is a prominent inventor based in Kawasaki, Japan. He has made significant contributions to the field of pharmaceutical crystallization, holding a total of 11 patents. His work focuses on the development of novel crystal forms of pharmaceutical compounds, which can enhance their efficacy and stability.

Latest Patents

Among his latest innovations are the Nateglinide M-type crystals. These crystals are produced by dissolving nateglinide in a solvent where it is highly soluble, followed by the addition of a solvent in which nateglinide is less soluble. The main peaks in the powder X-ray diffraction of these crystals are observed at 6.0°, 14.2°, 15.2°, and 18.8° (2θ). This innovative approach to crystallization has the potential to improve the performance of nateglinide in therapeutic applications.

Career Highlights

Michito Sumikawa has built a successful career at Ajinomoto Co., Ltd., where he has been instrumental in advancing the company's research and development efforts. His expertise in crystallization techniques has led to the successful patenting of multiple innovative solutions in the pharmaceutical industry.

Collaborations

Throughout his career, Sumikawa has collaborated with notable colleagues, including Yoshihito Koguchi and Takao Ohgane. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

In summary, Michito Sumikawa is a distinguished inventor whose work in pharmaceutical crystallization has led to significant advancements in the field. His contributions, particularly in the development of Nateglinide M-type crystals, highlight his commitment to improving pharmaceutical formulations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…